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PreviewsOf note, the two studies identify different
Eph receptors as key in CSC mainte-
nance, although some level of crosstalk
likely exists between the Eph receptors
as well as other RTKs central to mainte-
nance of the hierarchy. It would seem
this difference could not be due to differ-
ential representation within the recently
identified GBM subclasses as both
have highest expression in the mesen-
chymal and classical groups (Verhaak
et al., 2010). However, Eph receptors
may be informative within these
subgroups, although that hypothesis
would require further exploration. Impor-
tantly, both groups validate the efficacy
of targeting Eph receptors in preclinical
models.
In conclusion, these two reports are not
simply additions of new CSC markers butrather help reinforce expanding opportu-
nities for integrating features of normal
tissue hierarchies and instructive micro-
environmental cues in tumor develop-
ment and maintenance that can inform
advances in diagnosis and therapy.
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Chromosome rearrangements in B lymphocytes can be initiated by AID-associated double strand breaks
(DSBs), with others arising by unclear mechanisms. A recent study by Barlow and colleagues in Cell reports
on genomic regions, termed early replicating fragile sites, that may explain many AID-independent DSBs and
creates a compelling link between replication stress, transcription, and chromosome rearrangements.Recurrent chromosomal translocations
are common features of many cancers,
especially lymphomas and leukemias.
Most appear to be formed by the joining
of two double strand breaks (DSBs). In
developing B cells, DSBs are introduced
into immunoglobulin loci during V(D)J
recombination and class-switch recombi-
nation (CSR). Both CSR and immunoglob-
ulin somatic hypermutation are initiated
by AID, a single-strand-specific DNA cyti-
dine deaminase targeted to DNA by tran-
scription (Nussenzweig and Nussenz-
weig, 2010). AID-associated DSBs often
generate one of the two breakpoints in
the translocations observed in lymphoid
tumors. This programmed DNA damage
also puts the lymphocyte genome at riskfor rearrangements with bystander loci,
such as the C-MYC locus. Nonetheless,
while many translocations are driven by
off-target AID-induced DSBs, others
result from poorly defined factors that
might include replication errors, oxidative
stress, genotoxic agents, and involve-
ment of chromosome fragile sites.
Common fragile sites (CFSs) have been
recognized for decades as hotspots for
breaks occurring on metaphase chromo-
somes following replication stress (Durkin
and Glover, 2007). Following low doses of
the DNA polymerase inhibitor aphidicolin
(APH), chromosome breaks can be seen
at discrete genomic regions that span
hundreds of kilobases, often in large
genes. CFS instability is dependent onATR signaling and associated with other
DNA damage response factors (Durkin
and Glover, 2007). Le Beau et al. (1998)
and studies that followed showed that
CFSs replicate late in S-phase and some-
times escape to metaphase with incom-
plete replication. For decades, two nonex-
clusive models have existed for CFS
instability. One is that CFSs contain diffi-
cult-to-replicate sequences, leading to
stalled replication forks. The second is
that CFSs contain a paucity of replication
origins, leading to late or incomplete repli-
cation. Support for the former came from
the fact that CFSs are AT-rich and contain
a high number of ‘‘flexibility peaks’’ (Zlo-
torynski et al., 2003) capable of forming
secondary structures, especially whenFebruary 11, 2013 ª2013 Elsevier Inc. 137
Figure 1. Comparison of Replication Stress-Induced
Chromosome Breaks at ERFSs and CFSs
The difference in replication timing and the association with
specific transcribed genomic regions are illustrated. ERFSs
were found at regions that replicate early in S phase and are
associated with early firing replication origins, whereas CFS
regions replicate late and can be associated with intragenic,
inactive origins and/or poor firing of dormant origins.
Cancer Cell
Previewsreplication is perturbed, that can act
as barriers to replication. Recent
experiments (Letessier et al., 2011)
further provided evidence for a
paucity of active origins at some
CFSs, reflecting a failure to activate
dormant origins in these regions fol-
lowing replication fork arrest. Impor-
tantly, replication and fragility pat-
terns both differed among cell types.
Since their discovery, attempts
have been made to link CFSs to
translocations and other rearrange-
ments in cancers. Whereas positive
correlations were found at the chro-
mosomal level, most did not stand
up to higher resolution inspection.
Nonetheless, CFS instability has
been associated with gene amplifi-
cations and a small number of trans-
locations in cancers (Arlt et al.,
2006). Recently, replication stress
induced by APH or hydroxyurea
(HU) has been shown to be a potent
inducer of submicroscopic deletions
and duplications, i.e., copy number
variants (CNVs), with someCNVhot-spots at CFSs (Arlt et al., 2011). These
CNVs can spanhundreds of kilobases and
model many CNVs that arise frequently
in cancer cells and in the human germline.
Recently in Cell, Barlow et al. (2013)
opened a new chapter in the fragile site
and cancer saga that has important
implications for cancer risk. The authors
identified genome-wide early-firing repli-
cation origins, sites of RPAbinding indica-
tive of ssDNA accumulation and sites
of active transcription in mouse splenic B
cells after release from G1/S arrest in-
ducedwith high doses of HU.Comparison
of the data sets revealed a highly signifi-
cant overlap. Thus, HU-induced RPA
recruitment in early S phase preferentially
occurred at early origins of actively tran-
scribed genes. The sites were marked by
gH2AX binding and were associated with
BRCA1 and SMC5, indicative of replica-
tion fork collapse and DNA damage
response activation. The authors termed
these sites ‘‘early replicating fragile sites’’
(ERFSs) because their analysis focused
on the beginning of S phase, in contrast
to the late replication associated with
CFSs. Consistent with this difference,
ERFSs arose at different genomic loci
than previously mapped CFSs.
To investigate if ERFSs are prone
to chromosome breaks like CFSs, they138 Cancer Cell 23, February 11, 2013 ª2013treated cells with high-dose HU and
examined metaphases with FISH probes
to ERFS hotspots. All six ERFS hotspots
displayed CFS-like chromosomal breaks
with 8%–15% of total damage at these
six loci. Like CFSs, ATR inhibition and on-
cogene stress promoted ERFS breakage,
consistent with the arrested replication
and ssDNA observed at these sites. By
studying breakage at an ERFS near
SWAP70 in cell types with different levels
of transcription, the authors found a
positive correlation between fragility and
transcriptional activity despite similar
replication timing, supporting a mecha-
nistic link. Comparison of wild-type and
AID knockout B cells demonstrated that
ERFS fragility is AID independent.
How do ERFSs relate to chromosome
rearrangements in cancer? To address
this, the authors examined three ERFSs,
including one in the lymphoma-associ-
ated BACH2 locus, in metaphases from
AID-overexpressing, 53BP1-deficient B
cells, which have G1 IgH breaks that
persist into S phase where they might be
joined to ERFSs. They found chromo-
some breaks at both the IgH and BACH2
loci. Furthermore, BACH2 translocations
to unidentified chromosomes were found
in 1.2% of metaphases and to IgH in one
cell. They then compared ERFSs withElsevier Inc.copy number alterations (i.e.,
CNVs) detected in biopsies of
diffuse large B cell lymphoma, the
most common non-Hodgkin’s lym-
phoma. Strikingly, 51.6% of the
190 common amplifications and
deletions in the patient samples
overlapped with ERFS regions.
These studies have a number of
implications. First, they identify a
new class of fragile sites that are
similar to CFSs in terms of chromo-
some breaks, sensitivity to replica-
tion stress, and dependence on
ATR signaling. A notable difference
is that ERFSs are associated with
early replication origins, often in pro-
moters, whereasCFSs replicate late,
and at least some are associated
with poor firing of late and dormant
origins within large genes. A model
thus emerges in which impaired re-
plication is a universal contributor to
breakage and associated rearrange-
ments with the timing of replication
stress leading to different, cell type-
specific outcomes (Figure 1).Second, the association of ERFSs
with gene transcription is of great
interest. A similar association has been
made for some CFSs and transcription
of large genes (Helmrich et al., 2011).
These correlations are consistent with
recent findings (Dellino et al., 2013) that
suggest two classes of replication
origins: those associated with moderate
to high transcription levels and firing
in early S and those associated with
low transcription levels and firing
throughout S. These and other studies
raise important questions about the
mechanistic connections between repli-
cation, origin firing, and transcription
and the need to identify the genetic
factors and epigenetic modifications in-
volved. They also highlight the need
for a thorough evaluation of genomic
lesions in different cancer types based
on differential transcription of the regions
involved.
Finally, the association among ERFSs,
translocations, and CNVs in B cell
cancers is compelling. The data suggest
that ERFSs can provide AID-independent
DSBs that can partner with AID-induced
or other DSBs to promote translocations,
highlighting the importance of under-
standing the synergy between multiple
simultaneous intrinsic and exogenous
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Previewsgenotoxic factors. In addition, the strong
correlation of ERFSs with CNVs in B cell
lymphomas strengthens the argument
that common mechanisms likely underlie
what might initially appear as distinct
phenomena and suggest that replication
arrest at ERFSs can trigger CNV forma-
tion. This is indeed likely, because similar
CNVs that mimic constitutional and
cancer-related CNVs are induced in
human and mouse cells following replica-
tion stress, including at some CFSs (Arlt
et al., 2011). It would be interesting to
similarly examine de novo CNVs in B-
lymphocytes treated to express ERFSs.
The identity of the replication and repair
factors that create the rearrangements
and the endogenous conditions or envi-
ronmental agents that lead to replica-
tion stress are unclear. These are
important questions that are being ad-dressed with regard to human germline
CNVs and translocations, and they are
equally important to understanding rear-
rangements in the cancer genome and
the risk factors involved.ACKNOWLEDGMENTS
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ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while
achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors
will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer
therapies.The B cell lymphoma/leukemia 2 (BCL-2)
family regulates critical life or death deci-
sions of cells via the mitochondrial
pathway of apoptosis (Davids and Letai,
2012). BCL-2 inhibits death by binding
the BH3 domains of pro-death BCL-2
family proteins, thus preventing mito-
chondrial outer membrane permeabiliza-
tion, which can be considered the point
of commitment to apoptosis. BCL-2 has
several anti-apoptotic cousins, including
BCL-XL, BCL-w, and MCL-1, each of
which possesses a distinct, hydrophobic
BH3-binding pocket. Lymphoid malig-
nancies are frequently addicted to BCL-
2 for their survival. Because most of these
cancers, including chronic lymphocytic
leukemia (CLL), remain incurable withconventional therapies, agents that
specifically target BCL-2 are under urgent
investigation.
Early efforts to target the BCL-2 family
were met with disappointment in the
clinic. Agents such as the antisense
oligonucleotide oblimersen sodium and
the small molecule obatoclax showed
promise as BCL-2 antagonists in pre-
clinical testing but had little clinical
activity. A potential mechanistic short-
coming of these agents is that they were
never conclusively shown to specifically
engage their purported BCL-2 family
targets in patients.
Abbott Laboratories (now AbbVie) has
developed a series of BH3-mimetic small
molecules that bind to the BH3 bind-ing sites of anti-apoptotic proteins like
BCL-2. ABT-737, which binds BCL-2,
BCL-XL, and BCL-w, was the first
molecule studied extensively preclinically
(Oltersdorf et al., 2005). Many subsequent
experiments support its killing in an on-
target fashion in cell lines, primary
human cancer cells, and animal models.
ABT-263 (navitoclax) was the first of
this series to enter the clinic. Like
ABT-737, it binds BCL-2, BCL-XL, and
BCL-w, but it has the perceived
advantage of being orally bioavailable.
Clinical activity was observed, particularly
in lymphoid cancers (Roberts et al.,
2012); however, because navitoclax
binds not only to BCL-2 but also to
BCL-XL, the drug causes predictable,February 11, 2013 ª2013 Elsevier Inc. 139
